Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.

In previous studies, we have shown that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) could induce varying degrees of apoptosis in approximately two-thirds of human melanoma lines. In the present study, we have examined the sensitivity of fresh isolates and early passages of melanoma cells to TRAIL-induced apoptosis from eight patients. We found that fresh isolates were relatively resistant to TRAIL-induced apoptosis and that this appeared to be associated with low TRAIL death receptor (TRAIL-R) expression. TRAIL-R expression was also undetectable in tissue sections from the same melanoma. We attempted to create a model for these findings by generation of TRAIL-resistant melanoma lines from TRAIL-sensitive lines grown for prolonged periods in TRAIL. The resulting TRAIL-resistant melanoma cell lines had low TRAIL-R expression, and sensitivity to TRAIL was increased rapidly by pretreatment with proteasome inhibitors known to inhibit activation of nuclear factor-kappaB. However, the latter treatment had no significant effect on the sensitivity of fresh isolates to TRAIL. The levels of the inhibitors of apoptosis, Flice-like inhibitory protein and Bcl-2, also did not relate to resistance to TRAIL-induced apoptosis. These results suggest that down-regulation of TRAIL-R on melanoma cells may be the primary determinant of resistance of fresh isolates to TRAIL, and the basis for this requires further investigation.

[1]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[2]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[3]  P. Hersey,et al.  Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. , 1999, Cancer research.

[4]  I. Herr,et al.  Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .

[5]  P. Hersey,et al.  TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma Is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria1 , 2000, The Journal of Immunology.

[6]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[7]  K. Okumura,et al.  Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of  Type I IFNs , 1999, The Journal of experimental medicine.

[8]  T. Gura How TRAIL Kills Cancer Cells, But Not Normal Cells , 1997, Science.

[9]  P. Hersey,et al.  Immunohistological Examination Of The Relationship Between Metastatic Potential And Expression Of Adhesion Molecules And ‘Selectins’ On Melanoma Cells , 1994, Pathology.

[10]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[11]  S. Sharrow,et al.  Analysis of Flow Cytometry Data , 1991, Current protocols in immunology.

[12]  C. Heusser,et al.  Detection of intracellular cytokines by flow cytometry. , 1993, Journal of immunological methods.

[13]  P. Hersey,et al.  Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[15]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[16]  M. Weller,et al.  APO2 ligand: a novel lethal weapon against malignant glioma? , 1998, FEBS letters.

[17]  Tom Maniatis,et al.  The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.

[18]  P. Hersey,et al.  Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.

[19]  C. Smith,et al.  Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.

[20]  A. Fornace,et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.

[21]  A. Goldberg,et al.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.

[22]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[23]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[24]  P. Hersey,et al.  The Role of NF-κB in TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Melanoma Cells1 , 2001, The Journal of Immunology.

[25]  松原 弘樹,et al.  腎癌に対するTNF-related Apoptosis-inducing Ligand(TRAIL)を用いたアポトーシス誘導による分子標的治療の検討 , 2003 .

[26]  U. Zabel,et al.  Nuclear uptake control of NF‐kappa B by MAD‐3, an I kappa B protein present in the nucleus. , 1993, The EMBO journal.

[27]  S. Ruben,et al.  TRAIL ( Apo-2 L ) and TRAIL Receptors in Human Placentas : Implications for Immune Privilege 1 , 1999 .

[28]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.